NEW YORK (GenomeWeb News) — Quiatech, a developer of genetics-enabling technologies, has changed its name to Oligovation, the company said yesterday.
 
Oligovation said it has a modified RNA chemistry that improves synthesis conditions for RNA production, a specific reversible terminator for improving sequencing technology, and an in situ amplification technology for in vitro diagnostics.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.